Real‐World Outcomes of Polatuzumab Vedotin Plus R‐ <scp>CHP</scp> Versus R‐ <scp>CHOP</scp> ‐Based Regimens in Japanese Patients With Untreated Diffuse Large B‐Cell Lymphoma
PV-R-CHP may offer improved survival outcomes compared with R-CHOP in newly diagnosed DLBCL, particularly in patients with non-GCB, with an acceptable safety profile in a real-world setting. Although longer follow-up is required to confirm durability, these findings support the use of PV-R-CHP as a frontline treatment option.
Authors
- Tokiko Hoshiyama
- Atsushi Satake
- Ayako Iwama
- Yumiko Kono (ORCID: https://orcid.org/0000-0002-7977-0272)
- M. Hotta
- Tomoki Ito
- Shinya Fujita (ORCID: https://orcid.org/0000-0001-8014-7157)
- Yukie Tsubokura
- Hideaki Yoshimura
Institutions
- Kansai Medical University (JP)
Publication Details
- Journal
- Cancer Medicine
- Published
- 2026-01-01
- DOI
- https://doi.org/10.1002/cam4.71531
- Primary Topic
- Lymphoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Kansai Medical University